ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

デルマタン硫酸

Chondroitin Sulfate

HCID 24766
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
24967-93-9
標準SMILES
CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H](OS(=O)(=O)O)O[C@H]1O
InChIKey
KXKPYJOVDUMHGS-OSRGNVMNSA-N
分子式
C13H21NO15S
平均分子量
463.37 g/mol
単同位体質量
463.06319014

概要

Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. Chondroitin sulfate is composed of alternating 1,3-N-acetyl-β-d-galactosamine and 1,4-β-d-glucuronic acid units which bear 4-O- and/or 6-O-sulfations at the N-acetylgalactosamine units disposed of in specific patterns. Depending on the predominating disaccharide unit, it will present different biological activities. Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.

名称と識別子

優先名称
Chondroitin Sulfate
IUPAC
(2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
現地名
デルマタン硫酸
英語名
Chondroitin 4-sulfate
分子式
(C14H19NO14SNa2)n
分子量
499.38

名称と別名

Chondroitin sulfate9007-28-7Chondroitin, hydrogen sulfateCHEBI:37397(2S,3S,4S,5R,6R)-6-{[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-(sulfooxy)oxan-4-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid(2S,3S,4S,5R,6R)-6-(((2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-(sulfooxy)oxan-4-yl)oxy)-3,4,5-trihydroxyoxane-2-carboxylic acidRefChem:7109DTXSID8031021Sodium chondroitin sulfate39455-18-0Chondroitine sulfateChondroitin 4-sulfate sodium salt
名称をさらに表示
コンドロイチン硫酸Aコンドロイチン硫酸タイプAコンドロイチンスルファートコンドロイチン4-(水素スルファート)コンドロイチン硫酸Naコンドロイチン4-スルファートコンドロイチン硫酸A (JAN)デルマタン硫酸CHONDROITIN-4-SULFATECHONDROITIN SULFATE AturkadonChodroitin SulfatechondroitinasulfateChondroitinSulphateAchondroitinsulfatetypeaCSAChondroitin-4-sulfate
(2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acidMFCD00146419CondrosulfChondroitinsulfate CC13H21NO15SChondroitin 4 and 6 sulfateChondronStructum

物性

構造計算による物性補完中

XLogP
-4.8
極性表面積
267 Ų
水素結合供与体数
8
水素結合受容体数
15
回転可能結合数
6
重原子数
30
形式電荷
0
複雑度
739

実験および物理化学的性質

CosmeticsAntistatic; Hair conditioning
SolubilitySoluble
Melting Point190-194ºC
Dissociation Constants1.5-2

物理化学的性質

比旋光度
-28 to · D -28 to -32°
貯蔵温度
2 · 2-8°C
溶解性
2 O: · H2O: 0.1 g/mL、やや濁り、微黄色
化学的性質 · 1 件

化学的特性White or yellowish amorphous powder. Tasteless, odorless, hygroscopic, soluble in water, insoluble in organic solvents such as ethanol, acetone, ether, etc. Optical rotation -25°-+35°(c=1, H2O). There are characteristic absorption peaks at 725cm-1, 852cm-1 and 930cm-1 by infrared spectroscopy.

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 63.6% (7 of 11) of all reports.

Danger

H317 (36.4%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P317, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 11 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 4 件

Chemical: Chondroitin, hydrogen sulfate

XU - indicates a substance exempt from reporting under the Chemical Data Reporting Rule, (40 CFR 711).

Chondroitin, hydrogen sulfate, sodium salt: Does not have an individual approval but may be used under an appropriate group standard

Chondroitin hydrogen sulfate: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Chondroitin, hydrogen sulfate: Environment tier I assessment
Hazard Classes and CategoriesSkin Sens. 1 (36.4%)

安全データ

F
3-10
wgk
3
毒性
mouse,LD,oral,> 15gm/kg (15000mg/kg),Zhonghua Yixue Zazhi. Chinese Medical Journal. Vol. 58, Pg. 739, 1978.

化学と産業

薬理情報

ATC Code · 2 件

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingChondroitin sulfate protein binding reports have shown a very low percentage of protein binding of only 0.23% of the total protein.
Pharmacodynamics · 1 件

In clinical trials, chondroitin sulfate has been reported a significant pain relief. Some reports have shown no slow in joint damage. The effects of chondroitin sulfate have been very controversial. One of the characteristics of chondroitin is a slow onset of action with a maximal effect attained after several months. Chondroitin sulfate has been reported to have anti-inflammatory properties by reducing the synovitis and prevent proinflammatory cytokine up-regulation in arthritis models. It is also registered an anabolic effect of chondroitin sulfate in which it induces the synthesis of hyaluronate in synovial cells, it increases type II collagen and proteoglycan synthesis.

Mechanism of Action · 1 件

Chondroitin sulfate functions as a major component of the intricate extracellular matrix. It is proposed that chondroitin sulfate supply can provide new building blocks for the synthesis of new matrix components. The anti-inflammatory effect of chondroitin sulfate is thought to be caused by the inhibition of the synthesis of inflammatory intermediates such as the inhibition of nitric oxide synthase, COX-2, microsomal prostaglandin synthase 1 and prostaglandin E2. It is reported also an inhibitory activity in the toll-like receptor 4 which will later inhibit inflammatory cytokines, NFkB and MyD88. This activity suggests a modulation of the MAP kinase pathway. On the other hand, some reports have pointed out an induction on the PKC/PI3K/Akt pathway in neuroblastoma. The anabolic effect of chondroitin sulfate is suggested to be caused by the inhibition of metalloproteinases such as MMP-1, -3 and -13 as well as ADAMTS-4 and -5.

Biological Half-Life · 1 件

The approximate half-life of chondroitin sulfate and its derivative metabolites is 15 hours. After intramuscular administration of chondroitin sulfate in humans, the elimination half-life of the chondroitin sulfate was of 275 min. When administered orally, the elimination half-life was presented at 310 min.

関連反応

5 件
反応記録を作成
HRID 1003920 の反応式
HRID 1003920反応物として
HRID 1095260 の反応式
HRID 1095260反応物として
HRID 1714702 の反応式
HRID 1714702反応物として
HRID 1816867 の反応式
HRID 1816867反応物として
HRID 2239213 の反応式
HRID 2239213反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
24967-93-9、25322-46-7、39455-18-0、9007-28-7、9082-07-9
PubChem CID
24766
DTXSID
DTXSID601017238
ChEMBL
CHEMBL2303614、CHEMBL5266347
EC Number
232-696-9
Metabolism/Metabolites · 1 件

Chondroitin sulfate is not metabolized by cytochrome P450. Reports have indicated the presence in plasma of mono-, oligo- and polysaccharides with a molecular weight of less of 5 kDa which are derived from the partial digestion of exogenous chondroitin sulfate. The reported degradation of chondroitin sulfate seems to be very complex and led by the formation of smaller digestion derivatives of the original form.

Absorption, Distribution and Excretion · 3 件

Chondroitin sulfate is absorbed from the gastrointestinal tract. The absorbed portion reaches a ratio of 10% as unchanged chondroitin sulfate and 90% as depolymerized low-molecular-weight derivatives. This absorption depends on the sulfation status. The bioavailability of chondroitin sulfate ranges from 10-20% following oral administration. Reports have shown a consistent accumulation of the compound in joint tissue. The steady-state is attained after 3-4 days and it takes around 3-6 months to obtain the maximal effect. After intramuscular administration of chondroitin sulfate, the peak plasma level of 3.8 mcg/ml was reached after 90 min. When given orally, the peak plasma concentration of 4.6 mcg/ml was reached after 240 min.

Chondroitin sulfate is excreted in the urine as intact polymers and as partial degradation products. After intramuscular administration, about 37% of the administered dose is excreted by urine during the first 24 hours as high- and low-molecular-weight derivatives.

After intramuscular administration of chondroitin sulfate, the apparent volume of distribution was 0.40 ml/g. When administered orally, the apparent volume of distribution changed to 0.44ml/g.

用途と製造

Household ProductsInformation on 4 consumer products that contain Sodium chondroitin sulfate in the following categories is provided:
Use ClassificationCosmetics -> Antistatic; Hair conditioning
General Manufacturing InformationChondroitin, hydrogen sulfate: ACTIVE
応用分野 · 2 件

説明Chondroitin 4-sulfate is a natural polymer of a disaccharide consisting of glucuronic acid and N-acetyl glucosamine which is sulfated either in the 4 or 6 position. It is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA).

使用sodium chondroitin sulfate is described as a skin-conditioning agent, with possible anti-inflammatory properties. It can be found in such products as moisturizers and night skin care preparations. It is a derivative of natural mucopolysaccharides. Chondroitin 4-sulfate is an important structural component of cartilage and has been used as a dietary supplement to treat symptoms of joint discomfort.

上流・下流製品情報

上流原料

Strong acid styrene cation exchange resinタンパク質パンクレアチン

補足説明

定義本品は、天然のムコ多糖の誘導体のナトリウム塩である。

定義ChEBI: Chondroitin 4'-sulfate is a chondroitin sulfate in which the site of sulfation is carbon 4 of the N-acetylgalactosamine (GalNAc) sugar. It has a role as a mouse metabolite. It is a conjugate acid of a chondroitin 4'-sulfate anion.